AMDL is a clinical CAP/CLIA accredited molecular diagnostics laboratory at the Princess Margaret Cancer Center (PMCC), located on the 7th floor. The primary mission of AMDL is to support clinical trials and translational research projects requiring clinical-grade (CAP/CLIA) molecular testing at PMCC. AMDL works closely with our partner Molecular Diagnostics lab in Toronto General Hospital to transition protocols into clinical tests.
Since 2011, over
samples have been processed
Trusted by over
years of experience since 2011
In collaboration with the physicians at PMCC and the Cancer Genomics Program, the AMDL develops, evaluates, and implements high complexity genomic tests to meet the needs of clinical programs.
Don't see what you need? Please contact us.
AMDL helps support our clients by providing tailored services and study-specific requisitions. We offer a variety of services to support research activities, including nucleic acid extraction and banking, next-generation sequencing (Illumina and Ion Torrent platforms), NanoString, ddPCR, MLPA, and Sanger sequencing. Please see below for our current testing menu or contact us for more information.
Processing and extraction along with CAP/CLIA sample banking.
FFPE Tumour tissue with 25mm2 tumour tissue
surface area (minimum 10mm2) and with minimum 30%
nucleated tumour cells
|Blood/Bone Marrow||1 ml|
|Plasma (Streck)||1 full streck tube (8-10ml)|
|RNA (PAXgene)||1ml (8ml total once mixed with the buffer in the tube)|
|Nucleic Acids||Assay dependent - Please contact the laboratory to inquire|
|Cell suspensions/pellets, lines (or fixed cells/cell lines)||Assay dependent - Please contact the laboratory to inquire|
|Saliva||Full Oragene collection tube (saliva to "Fill line" on OG-500 tube, mixed with stabilizers included in integrated lid)|
A comprehensive investigation of cancer genes and selected non-cancer genes within patient blood and tumour samples can provide information about diagnosis, patient risk stratification and response to therapy, as well as help determine potential application of targeted therapies for different malignancies.
NanoString technology enables the direct detection of RNA, DNA or protein in a sample using patented molecular barcodes and a unique hybridization and detection platform.
Custom 17 gene panel for stratifying acute myeloid leukemia
(AML) patients for their level of relapse risk. Read more about
Platform: NanoString nCounter
ddPCR enables the quantitation of nucleic acids in a sample using a miniaturized PCR procedure that is executed in a high-throughput manner.
Design advice for your clinical research assay and validation and testing according to CAP/CLIA guidelines
a list of select projects we participated in
Ontario-wide Cancer Targeted Nucleic Acid Evaluation (OCTANE) tumour profiling initiative led by Dr. Phil Bedard.
Prevent Ovarian Cancer Project (POCP) study for early detection of ovarian cancer, led by Dr. Marcus Bernardini.
Gynecologic cancers molecular profiling initiatives led by Drs. Amit Oza and Stéphanie Lheureux.
Study for NSCLC expanded molecular profiling, and detection of resistance mutations in ctDNA, led by Dr. Natasha Leighl.
Study using the Leukemia Stem Cell 17-gene signature (LSC17) assay developed by Dr. John Dick and Jean Wang, with study led by Drs. Steven Chan and Jean Wang.
Myeloma study examining circulating tumour DNA, led by Dr. Suzanne Trudel.
Saliva DNA profiling using a custom NGS panel of 295 genetic variants relevant to breast cancer risk.
Please contact the lab director to discuss your clinical research project and how we can help.
AMDL offers several different advanced technologies to provide interpretable results. Details about these technologies and custom panels can be found in the ‘Our Services’ section. Information about commercially available panels can also be found on vendors’ websites. Please contact us so we can discuss and assist you with meeting your research objectives.
The annotation team uses the variant assessment software Alissa Interpret (Agilent Technologies) to manage cases and variants for reporting, while gathering and reviewing evidence from curated variant and gene databases, human disease knowledge resources and clinical and scientific literature. Variants are classified based on the available evidence of the variant’s degree of clinical actionability of the somatic variants (Sukhai et al., Genet Med. 2016) or pathogenicity of the germline variants (Richards et al., Genet Med. 2015).
We will get in touch with you shortly.